Treatment of Newly Diagnosed Myeloma - Transplant Eligible

P-131: Daratumumab (dara) as maintenance therapy after autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): Results of a phase 2 study

P-132: Post-induction Undetectable Flow Minimal Residual Disease ameliorates the high risk determined by FISH among Newly Diagnosed Multiple Myeloma

P-133: Validation of two International Myeloma Staging Systems: Second Revision of ISS and Mayo Additive Staging Sytems (MASS) in an external cohort of Ankara University

P-134: Clonal Isotype Switch predicts long-term survival in Multiple Myeloma after Autologous Stem Cell Transplantation.

P-135: Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)

P-136: Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma

P-137: A phase 3, two-stage, randomized study of iberdomide maintenance versus lenalidomide maintenance post autologous stem cell transplantation in newly diagnosed multiple myeloma: EXCALIBER-Maintenance

P-138: Online CME improves clinical decision-making in the management of patients with multiple myeloma

P-139: Impact of Melphalan Staggered Dosing Prior to Autologous Hematopoietic Cell Transplantation for Multiple Myeloma Patients

P-140: MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY

P-141: Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients

P-145: Early M protein immune reconstitution is a good prognostic marker for patients with high-risk cytogenetic multiple myeloma after autologous hematopoietic stem cell transplantation

P-146: MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma

P-147: Obtaining M protein immune reconstitution as soon as possible after Tandem autologous hematopoietic stem cell transplantation improves the prognosis of patients with Newly diagnosis multiple myeloma

P-148: On-demand plerixafor added to high-dose cyclophosphamide and Pegfilgrastim in the mobilization of patients with multiple myeloma: High effectiveness and affordable cost

P-151: Demographic and Clinical Characteristics of Multiple Myeloma Patients in a Tertiary Cancer institute of India

P-152: Attrition Rates in Multiple Myeloma and factors influencing patient dropouts at a tertiary referral center in India.

P-153: Maintenance therapy with carfilzomib, pomalidomide and dexamethasone (KPd) in high-risk myeloma patients (pts): A Phase 2 study with a safety run-in

P-154: Biomarker utility of circRNAs in multiple myeloma: The exemplary cases of ciRS-7 and circCCT3 as surrogate prognostic molecular biomarkers combined with the R-ISS staging system

P-155: Comparative Analysis of Outcomes in Patients with CRAB versus SLiM Criteria at Diagnosis of Multiple Myeloma

P-156: OUTCOMES OF A BORTEZOMIB-BASED INDUCTION REGIMEN (SEQUENTIAL OR UPFRONT TRIPLE ASSOCIATION WITH LENALIDOMIDE) IN TRANPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

P-157: How public policies have improved the overall survival of transplant eligible newly diagnosed multiple myeloma patients in the Chilean public health system

P-158: EXPERIENCE AT SON ESPASES UNIVERSITARY HOSPITAL WITH DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (D-VRd) AS FIRST LINE TREATMENT IN MULTIPLE MYELOMA

P-161: IMPACT OF INDUCTION TREATMENT ON THE SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA CANDIDATES FOR AUTOLOGOUS STEM CELL TRANSPLANTATION. EXPERIENCE OF A CENTER.

P-163: Treatment Patterns and Outcomes in Newly Diagnosed Multiple Myeloma

P-164: Reduction in Disease Symptoms/Impacts After Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Treatment for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma (GRIFFIN Study)

P-165: Incidence, risk factors and impact of supraventricular tachycardia (SVT) with high dose therapy melphalan among myeloma patients undergoing autologous stem cell transplant (HDT/ASCT)

P-169: CLINICAL FEATURES AND OUTCOME PATTERNS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WHO ARE CANDIDATE FOR TRANSPLANT: A SINGLE CENTER EXPERIENCE IN PARAGUAY

P-170: Stem cell mobilization and autologous stem cell transplantation after induction with bendamustine, prednisone and bortezomib (BPV) in 135 untreated myeloma patients with variable renal function

P-171: The changing landscape of peri-transplant adverse events with HDT/ASCT and the impact on long term outcomes for myeloma patients